Initiated Overweight X

GH Guardant Health

Barclays

$60

Upgrades Neutral Buy X

GH Guardant Health

Guggenheim

$36

Resumed Buy X

GH Guardant Health

Jefferies

$32

Resumed Buy X

GH Guardant Health

Craig Hallum

$28

Initiated Neutral X

GH Guardant Health

Guggenheim

Initiated Peer Perform X

GH Guardant Health

Wolfe Research

Upgrades Mkt Perform Outperform X

GH Guardant Health

Raymond James

$27

Initiated Outperform X

GH Guardant Health

Bernstein

$34

Upgrades Neutral Overweight X

GH Guardant Health

Piper Sandler

$40

Resumed Overweight X

GH Guardant Health

JP Morgan

$65

Upgrades Neutral Buy X

GH Guardant Health

Citigroup

$28 $40

Initiated Buy X

GH Guardant Health

UBS

$40

Downgrades Buy Neutral X

GH Guardant Health

Citigroup

$60 $33

Initiated Sector Outperform X

GH Guardant Health

Scotiabank

$36

Downgrades Overweight Neutral X

GH Guardant Health

Piper Sandler

$65 $50

Initiated Buy X

GH Guardant Health

Craig Hallum

$88

Initiated Overweight X

GH Guardant Health

Stephens

$99

Initiated Outperform X

GH Guardant Health

Credit Suisse

$80

Initiated Overweight X

GH Guardant Health

Piper Sandler

$65

Resumed Buy X

GH Guardant Health

BTIG Research

$135 $115

Resumed Outperform X

GH Guardant Health

Cowen

$170

Initiated Mkt Perform X

GH Guardant Health

Raymond James

Initiated Buy X

GH Guardant Health

Goldman

$160

Initiated Overweight X

GH Guardant Health

Wells Fargo

$145

Initiated Buy X

GH Guardant Health

Stifel

$175

Reiterated Buy X

GH Guardant Health

Canaccord Genuity

$96 $125

Initiated Buy X

GH Guardant Health

Canaccord Genuity

$90

Upgrades Neutral Buy X

GH Guardant Health

BofA/Merrill

$81 $84

Reiterated Neutral X

GH Guardant Health

BofA/Merrill

$42 $60

Initiated Neutral X

GH Guardant Health

BofA/Merrill

$37

Initiated Overweight X

GH Guardant Health

JP Morgan

$42

Initiated Outperform X

GH Guardant Health

William Blair

GH  Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA. The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.